Market Cap
€111.4b
Last Updated
2020/07/12 20:52 UTC
Data Sources
Company Financials +
Executive Summary
Sanofi provides therapeutic solutions worldwide.
Rewards
Risk Analysis
Snowflake Analysis
Average dividend payer and fair value.
Similar Companies
Share Price & News
How has Sanofi's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SAN has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-2.3%
SAN
-1.9%
FR Pharmaceuticals
-0.4%
FR Market
1 Year Return
21.0%
SAN
16.3%
FR Pharmaceuticals
-8.9%
FR Market
Return vs Industry: SAN exceeded the French Pharmaceuticals industry which returned 16.3% over the past year.
Return vs Market: SAN exceeded the French Market which returned -8.9% over the past year.
Shareholder returns
| SAN | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.3% | -1.9% | -0.4% |
| 30 Day | -0.1% | 0.5% | 3.6% |
| 90 Day | 8.3% | 10.2% | 11.5% |
| 1 Year | 25.4%21.0% | 20.3%16.3% | -7.1%-8.9% |
| 3 Year | 19.0%5.1% | 14.3%2.0% | 9.1%0.07% |
| 5 Year | 9.4%-10.2% | 10.1%-8.7% | 23.1%6.5% |
Price Volatility Vs. Market
How volatile is Sanofi's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Sanofi's (EPA:SAN) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?1 month ago | Simply Wall St
How Much Of Sanofi (EPA:SAN) Do Institutions Own?1 month ago | Simply Wall St
An Intrinsic Calculation For Sanofi (EPA:SAN) Suggests It's 32% UndervaluedValuation
Is Sanofi undervalued compared to its fair value and its price relative to the market?
21.7%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SAN (€88.92) is trading below our estimate of fair value (€113.56)
Significantly Below Fair Value: SAN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SAN is poor value based on its PE Ratio (32.2x) compared to the XE Pharmaceuticals industry average (24.1x).
PE vs Market: SAN is poor value based on its PE Ratio (32.2x) compared to the French market (14.9x).
Price to Earnings Growth Ratio
PEG Ratio: SAN is poor value based on its PEG Ratio (12.1x)
Price to Book Ratio
PB vs Industry: SAN is good value based on its PB Ratio (1.9x) compared to the FR Pharmaceuticals industry average (2.6x).
Next Steps
Future Growth
How is Sanofi forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
2.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SAN's forecast earnings growth (2.7% per year) is above the savings rate (0.6%).
Earnings vs Market: SAN's earnings (2.7% per year) are forecast to grow slower than the French market (13.1% per year).
High Growth Earnings: SAN's earnings are forecast to grow, but not significantly.
Revenue vs Market: SAN's revenue (3.5% per year) is forecast to grow slower than the French market (3.9% per year).
High Growth Revenue: SAN's revenue (3.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SAN's Return on Equity is forecast to be low in 3 years time (12.6%).
Next Steps
Past Performance
How has Sanofi performed over the past 5 years?
-6.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SAN has a large one-off loss of €3.6B impacting its March 31 2020 financial results.
Growing Profit Margin: SAN's current net profit margins (9%) are lower than last year (12.2%).
Past Earnings Growth Analysis
Earnings Trend: SAN's earnings have declined by -6.7% per year over the past 5 years.
Accelerating Growth: SAN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SAN had negative earnings growth (-22%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (7%).
Return on Equity
High ROE: SAN's Return on Equity (5.9%) is considered low.
Next Steps
Financial Health
How is Sanofi's financial position?
Financial Position Analysis
Short Term Liabilities: SAN's short term assets (€28.9B) exceed its short term liabilities (€20.4B).
Long Term Liabilities: SAN's short term assets (€28.9B) do not cover its long term liabilities (€33.2B).
Debt to Equity History and Analysis
Debt Level: SAN's debt to equity ratio (41.8%) is considered high.
Reducing Debt: SAN's debt to equity ratio has increased from 26.2% to 41.8% over the past 5 years.
Debt Coverage: SAN's debt is well covered by operating cash flow (31.4%).
Interest Coverage: SAN's interest payments on its debt are well covered by EBIT (15.3x coverage).
Balance Sheet
Next Steps
Dividend
What is Sanofi current dividend yield, its reliability and sustainability?
3.54%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: SAN's dividend (3.54%) is higher than the bottom 25% of dividend payers in the French market (1.72%).
High Dividend: SAN's dividend (3.54%) is low compared to the top 25% of dividend payers in the French market (4.89%).
Stability and Growth of Payments
Stable Dividend: SAN's dividends per share have been stable in the past 10 years.
Growing Dividend: SAN's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (114.1%), SAN's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: SAN's dividends in 3 years are forecast to be well covered by earnings (49.5% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
8.9yrs
Average management tenure
CEO
Paul Hudson (53yo)
0.83
Tenure
€5,691,899
Compensation
Mr. Paul Hudson serves as Chief Executive Officer and Director at Sanofi since September 1, 2019. Mr. Hudson was Chief Executive Officer of Novartis Pharmaceuticals at Novartis AG since July 1, 2016 until ...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD6.44M) is above average for companies of similar size in the French market ($USD3.90M).
Compensation vs Earnings: Insufficient data to compare Paul's compensation with company performance.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 0.83yr | €5.69m | 0.00045% €501.3k | |
| Executive VP & CFO | 1.75yrs | no data | no data | |
| Principal Accounting Officer and Vice President of Corporate Accounting | no data | no data | no data | |
| Chief Information officer | 8.92yrs | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Executive VP of Legal Affairs & General Counsel | 13.33yrs | no data | no data | |
| Global Compliance Officer & VP | 8.25yrs | no data | no data | |
| Head of Communications | no data | no data | no data | |
| Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing | 15.92yrs | no data | no data | |
| Senior Vice President of Audit & Internal Control Assessment | 18.17yrs | no data | no data |
8.9yrs
Average Tenure
61yo
Average Age
Experienced Management: SAN's management team is seasoned and experienced (8.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 0.83yr | €5.69m | 0.00045% €501.3k | |
| Independent Director | 3.17yrs | €137.68k | 0.000080% €89.1k | |
| Independent Director | 9.58yrs | €132.93k | 0.000080% €89.1k | |
| Honorary Chairman | 10.17yrs | €4.71m | no data | |
| Independent Chairman | 10.17yrs | €708.04k | 0.00013% €144.8k | |
| Independent Director | 6.17yrs | €159.04k | 0.000080% €89.1k | |
| Independent Director | 7.17yrs | €137.68k | 0.000080% €89.1k | |
| Independent Director | 4.17yrs | €223.13k | 0.000090% €100.3k | |
| Director | 8.17yrs | €140.05k | 0.000080% €89.1k | |
| Independent Director | 4.17yrs | €147.17k | 0.000090% €100.3k |
6.7yrs
Average Tenure
63.5yo
Average Age
Experienced Board: SAN's board of directors are considered experienced (6.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Sanofi's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Sanofi
- Ticker: SAN
- Exchange: ENXTPA
- Founded: 1994
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €111.399b
- Shares outstanding: 1.25b
- Website: https://www.sanofi.com
Number of Employees
Location
- Sanofi
- 54, Rue La BoEtie
- Paris
- Ile-de-France
- 75008
- France
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SNYN.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | May 1999 |
| SAN | ENXTPA (Euronext Paris) | Yes | Ordinary Shares | FR | EUR | May 1999 |
| SNW | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | May 1999 |
| SAN | SWX (SIX Swiss Exchange) | Yes | Ordinary Shares | CH | CHF | May 1999 |
| 0O59 | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | EUR | May 1999 |
| SANF | BIT (Borsa Italiana) | Yes | Ordinary Shares | IT | EUR | May 1999 |
| SNW | XTRA (XETRA Trading Platform) | Yes | Ordinary Shares | DE | EUR | May 1999 |
| SANP | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | EUR | May 1999 |
| SANO | WBAG (Wiener Boerse AG) | Yes | Ordinary Shares | AT | EUR | May 1999 |
| SNY | NasdaqGS (Nasdaq Global Select) | ADR ECH REP 1/2 ORD EUR2 SPON | US | USD | Jul 2002 | |
| SNW2 | DB (Deutsche Boerse AG) | ADR ECH REP 1/2 ORD EUR2 SPON | DE | EUR | Jul 2002 | |
| SNY N | BMV (Bolsa Mexicana de Valores) | ADR ECH REP 1/2 ORD EUR2 SPON | MX | MXN | Jul 2002 | |
| 0A2V | LSE (London Stock Exchange) | ADR ECH REP 1/2 ORD EUR2 SPON | GB | USD | Jul 2002 |
Biography
Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; and Kymera Therapeutics. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/07/12 20:52 |
| End of Day Share Price | 2020/07/10 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.